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ABSTRACT
Objective: The objective of this selective EBM review is to determine whether or not
Bevacizumab is an effective treatment in inhibiting the growth of recurrent pterygium.
Study Design: Review of three published, English language randomized controlled trials
published in 2010, 2012, and 2013.
Data sources: Three randomized controlled trials measuring the efficacy of Bevacizumab to
inhibit the growth of recurrent pterygium were found using PubMed and OVID databases.
Outcome(s) Measured: The severity and progression of pterygium recurrence as well as corneal
neovascularization were the main outcomes measured. Conjunctival injection, thickness, and size
of the fibrovascular tissue were examined in subjects using ophthalmic evaluation including
visual acuity testing, applanation tonometry, lit-lamp biomicroscopic examination, slit-lamp
photography, indirect ophthalmoscopy, and corneal photographs.
Results: In the study by Fallah, all groups failed, meaning fibrovascular tissue stretched onto the
cornea. However, the mean duration for invasion of cornea in study group patients was
significantly longer than for control group patients. The study by Lekhanont showed that
Bevacizumab significantly transiently decreased the conjunctival injection. However, true
recurrence was found in 62 of 80 patients with no statistically significant difference among the
groups. In the study by Ozgurhan, pterygium recurrence was not noted in any patients in the
study group, but was noted in 2 of 22 eyes in the control group. Moreover, corneal
neovascularization was noted in 5 of 22 eyes in the control group but in none of the patients of
the study group.
Conclusion: The results of two of the randomized trials showed that Bevacizumab delays the
recurrence of impending recurrent pterygium, but does not completely inhibit it. One of the
randomized trials showed that Bevacizumab was an effective therapy for reducing recurrent
pterygium and corneal neovascularization, but results were not statistically significant. Overall
consistency was not provided and the data was inconclusive. All trials were limited due to small
sample size and lack of follow-up studies.
Key Words: Recurrent pterygium; Bevacizumab; Avastin; VEGF
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INTRODUCTION
Pterygium is a proliferative conjunctival lesion that consists of fibrovascular tissue and
extends onto the cornea. It can cause significant astigmatism and severe visual impairment.6
Recurrent pterygium, which is not uncommon after pterygium excision surgery, can be more
symptomatic and problematic to eliminate than primary pterygium.6 This systematic review
evaluates three randomized controlled trials comparing the efficacy of Bevacizumab for
inhibiting the growth of recurrent pterygium.
In 2013, the prevalence of pterygium worldwide was estimated to be 10.2%. 9 Prevalence
varies depending on the population studied, and it is more common in tropical regions.6 Within
the U.S., prevalence rates vary from less than 2% to between 5% and 15% depending on
locations.12 Increased age and sun exposure are risk factor for the development of this lesion.6
Pterygium is usually managed by ophthalmologists, but it may be initially identified and
treated by general practitioners. There are relatively few Physician Assistants (PAs) working in
ophthalmology today.7 However, the U.S. is currently facing a projected shortage of
ophthalmologists, and one solution may be for ophthalmologists to work with more PAs.7 The
exact healthcare cost of pterygium has not been specified; however, the cost of vision-related
diseases in 2013 was estimated to be $139 billion.1 The average cost of pterygium excision
surgery with grafting is estimated to be $3,000.3 An exact number of healthcare visits for
pterygium was not specified; however, the number of ambulatory care visits for disorders of the
eye and adnexa, excluding glaucoma, cataract, disorders or refraction and accommodation,
conjunctivitis, and disorders of eyelids, was 11,899 in 2009.2
The natural history, etiology, and pathogenesis of pterygium are poorly understood. It is
unclear how pterygium converts from active, which refers to growing over months to years, to
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inactive, which refers to static without increase in size.6 It is believed that angiogenesis plays a
key role in the formation of fibrovascular tissue in recurrent pterygium.10 The most common
symptoms of pterygium range from none to redness, irritation, pruritus, discomfort, swelling, and
blurring of vision.6 Pterygium may induce astigmatism, and it can cause adverse effects on vision
if proliferation reaches the visual axis.6,12 Patients with a small pterygium are treated
symptomatically with ocular lubricants; larger lesions that impair visual acuity or eye movement
are treated by surgical excision of the lesion.6 Recurrence rates after pterygium surgical excisions
are high, and the recurrent lesions may be more inflamed or grow larger than the initial lesions.6
Intraoperative and postoperative adjunctive treatment modalities to prevent recurrence of
pterygium currently used include mitomycin C, 5-fluorouracil, corticosteroids, and beta
irradiation.4 Currently used adjunctive measures decrease recurrence rates substantially, but
reported rates vary widely, and none have been proven to be completely safe and effective.4
Pterygium recurrences and repeated excisions can lead to disruption of the ocular surface and
subsequent complications.6 As mentioned earlier, angiogenesis has been noted to be a factor in
pterygium formation and progression.10 Vascular endothelial growth factor (VEGF) is one of the
most important factors in angiogenesis; therefore, blocking this factor may inhibit
angiogenesis.10 Bevacizumab is an anti-VEGF agent and is thought to have potential value in the
inhibition of growth of recurrent pterygium by inhibiting angiogenesis.
OBJECTIVE
The objective of this selective EBM review is to determine whether or not Bevacizumab
is an effective treatment in inhibiting the growth of recurrent pterygium.
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METHODS
This review consists of three prospective, randomized controlled trials that met certain
criteria. The population studied included subjects over 18 years old who developed recurrent
pterygium after pterygium surgical excision. Two of the studies reviewed compared
Bevacizumab to topical corticosteroids (Lekhanont8, Fallah4) and one of the studies compared
Bevacizumab to artificial tears (Ozgurhan10). More specifically, the interventions compared in
the study by Ozgurhan were the use of topical Bevacizumab (5mg/mL) QID x 2mo vs. artificial
tears QID x 2mo; this was a double blinded study, and the administration of both interventions
took place one month after subjects had recurrent pterygium excision surgery. Lekhanont
compared using a single intralesional subconjunctival injection of Bevacizumab at 3 different
doses: 1.25 mg/0.05mL; 2.5mg/0.1mL; 3.75mg/0.15mL vs. topical 0.1% fluorometholone eye
drops QID x 4wks. Finally, Fallah compared the use of 1 eye drop of Bevacizumab 5mg/mL BID
with betamethasone QID for 1 week vs. betamethasone QID for 1 week only.
The outcomes measured in all three studies were all based on patient oriented evidence
that matters (POEMS). The progression and severity of the pterygium in subjects’ eyes after
having had pterygium excision surgery was the main outcome measured. The severity of
impending recurrent pterygia was measured by looking at conjunctival injection thickness, size
and thickness of fibrovascular tissue, and scleral vessels as well as corneal neovascularization.
Side effects and complications after applying treatment were also measured to assess the safety
and tolerability of Bevacizumab for the treatment of pterygium.
Key words used to research for this topic included recurrent pterygium, Bevacizumab,
Avastin, and VEGF. All three articles were published in English, and published in peer-reviewed
journals. The author researched the articles using PubMed, OVID, and COCHRANE databases.
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Articles were selected based on their relevance to the author’s clinical question and whether they
included POEMS. Inclusion criteria during the author’s research included randomized controlled
trial prospective studies published after 1999. The three studies selected were published between
2010 and 2013. Exclusion criteria included studies that included subjects under 18 years old with
a past medical history of any ocular surface disease or any other ocular surgery besides the ones
being currently studied. The statistics reported and used were numbers needed to treat (NNT),
relative benefit increase (RBI), absolute benefit increase (ABI), relative risk increase (RRI),
absolute risk increase (ARI), numbers needed to harm (NNH), and p-values.
Table 1: Demographics and Characteristics of Included Studies
Study

Type

#
Pts

Age
(yrs)

Inclusion
Criteria

Exclusion
Criteria

W/D

Interventions

Ozgurhan,
2013

RCT

44

2077

Pts. 18 years
and older who
had recurrent
pterygium as
well as the
ability to
provide
written
informed
consent and
to comply
with
assessments
for the full
duration of
the study.

History of a
major
systemic
condition or
any ocular
surface
disease
besides
pterygium,
uveitis,
retinal
vascular
diseases, and
previous
conjunctival
or scleral
surgery

0

Use of topical
bevacizumab
(5mg/mL) QID
x 2mo VS.
artificial tear
QID x 2mo
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Lekhanont,
2012

RCT

80

3167

Impending
recurrent
pterygium
developed
within 6
months after
pterygium
surgery
Failure of
conventional
topical antiinflammatory
therapy for
impending
recurrent
pterygium.
18y or older
and good
compliance
with study
regimen.

Hx of any
adjunctive
treatment,
such as
mitomycin C.
Other ocular
surface
pathologies
or coexisting
ocular
diseases.
Hx of allergy
to the
medications
used in the
study.
Other ocular
surgeries
within the
previous
6mo.

0

Single
intralesional
subconjunctival
injection of
Bevacizumab at
3 different
doses: 1.25
mg/0.05mL;
2.5mg/0.1mL;
3.75mg/0.15mL
VS Topical
0.1%
fluorometholone
eye drops QID x
4wks

Fallah,
2010

RCT

54

>18

Pts. Who had
undergone
pterygium
excision and
developed
impending
recurrent
pterygium.

Anterior
surface
complications
or any other
ocular
surgery. Pts.
With platelet
disorders or
HTN.

0

1 Eye drop of
bevacizumab
5mg/mL BID
with
betamethasone
QID for 1 week
VS
Betamethasone
QID for 1 week
only

OUTCOMES MEASURED
The main outcome measured was an increase in the size of fibrovascular tissue or true
pterygium recurrence, which was defined by conjunctival fibrovascular tissue extending onto the
cornea. The severity of impending recurrent pterygium was assessed depending on the scoring of
conjunctival injection, thickness, and size of the fibrovascular tissue. Neovascularization was
assessed by the presence of new vessels extending onto the cornea without conjunctival fibrous
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tissue. Subjects underwent ophthalmic evaluation including visual acuity testing, applanation
tonometry, lit-lamp biomicroscopic examination, slit-lamp photography, indirect
ophthalmoscopy, and corneal photographs. Visual analog scales were used to evaluate symptoms
and signs such as ocular irritation. These were recorded in a double-blinded fashion. Adverse
reactions and complications were compared between study groups.
RESULTS
In the study by Ozgurhan, 44 eyes of 44 subjects at the Beyoglu Eye Research and
Training Hospital, located in Istanbul, Turkey, were studied for a total of 6 months. Subjects
were seen before having recurrent pterygium excision surgery, and were thereafter seen at 1 day,
1 week, 1 month, 2 months, 3 months, and 6 months after surgery. Treatments were applied at
the 1month follow up visit. No instances of pterygium recurrence were noted in the study group,
whereas recurrence in 1 eye was noted 1month after treatment in the 2 month follow up visit, and
one additional recurrence was noted 2 months after treatment in the 3 month follow up visit. A
total recurrence in 2 eyes of the control group was present at the 6 month follow up visit.
However, this was not considered to be statistically significant (p=0.244). The patients in the
control group who failed received topical Bevacizumab, which resulted in the inhibition of the
advancement of their pterygium.
Corneal neovascularization was not seen in the patients in the study group. However, it
was seen in 4 eyes of the control group in the 2 month follow up visit (p=0.053), and in 1 eye in
the 3month follow up visit (p=0.024). A total of 5 eyes in the control group developed corneal
neovascularization by the 6 month follow up visit (p=0.024); a statistical significant was noted
between treatment and control groups based on the p value. Topical Bevacizumab was also given

De la Cruz: Bevacizumab and Pterygium 7
to these patients in the control group who failed, which prevented corneal neovascularization
from advancing and even thinned some of the vessels.
None of the subjects withdrew from the experiment, and all of the subjects’ results were
provided. SPSS version 16 was used for statistical analysis. The calculations for efficacy and
safety can be seen in Table 2. The NNT was calculated to be -11 and is interpreted as followed:
for every 11 patients treated with Bevacizumab, one fewer would experience inhibition in
pterygium recurrence compared to control. There were no systemic or ocular side effects
experienced by subjects who were administered the topical Bevacizumab. To measure safety of
these medications, NNH was calculated and the result was -4. This would be interpreted as
followed: For every 4 patients treated with Bevacizumab, one less would experience adverse
effects.
Table 2: Bevacizumab and Pterygium Ozgurhan Study10
CER

EER

RBI

ABI

NNT

p-value

0.09

0

-1

-0.09

-11

0.244

CER

EER

RRI

ARI

NNH

p-value

22.7%

0%

-1

-22.7%

-4

0.024

In the study by Lekhanont, 80 eyes of 80 subjects were recruited in the eye clinic at the
Ramathibodi Hospital, Bangkok, Thailand. Subjects chosen had developed recurrent pterygium
in a mean time of 2.5 months after having pterygium excision surgery. Each treatment was given
to subjects and then followed from 3-18 months. 3 days after application of the respective
treatments, conjunctival injection significantly decreased in all treatment groups. 1 week after
treatment, only the groups who received 2.5mg and 3.75mg of Bevacizumab continued to show a
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significant reduction in conjunctival vascularization. Decrease in conjunctival injection was
observed until 2 weeks for the group who received 2.5mg of Bevacizumab, and until 3 weeks for
the group that received the highest dose of Bevacizumab, 3.75mg. At later points, conjunctival
hyperemia increased back to its pre-injection states at later time points. Patients in the control
group who received the topical corticosteroid only showed no regression of vessels at any point
during the duration of the study.8
No significant difference in the mean severity score improvement among the treatment
groups was observed, and no change in thickness and size of the pterygia was noted at any
Bevacizumab doses during the study. At the 3 month follow up, true pterygium recurrence was
found in 62 subjects. No statistically significant difference in the recurrence rate was noted
among the groups (p=0.82). Recurrent pterygia showed to have a greater fibrovascular
proliferative response than the original pterygia, and rebound hyperemia and inflammation were
seen in the majority of the subjects. Side effects from the Bevacizumab treatment included pain
after injection and subconjunctival hemorrhage; these were noted in 3 subjects.
A single subconjunctival Bevacizumab injection was effective in temporarily reducing
conjunctival vascularization in impending recurrent pterygium; it had no effect on the size and
thickness of the lesions. It was shown that Bevacizumab is unlikely to reduce the recurrence rate
for impending recurrent pterygium. Statistical analysis was performed using SPSS version 14;
Paired t test and Wilcoxon signed rank test were also used to determine the significance of
changes after treatment. Results for calculations of efficacy and safety can be seen in Table 3.
The NNT for this study is 4 and is interpreted as followed: For every 4 patients treated with
Bevacizumab, one additional patient will have inhibition of the pterygium.
Table 3: Bevacizumab and Pterygium: Lekhanont Study8
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CER

EER

RBI

ABI

NNT

p-value

80%

75%

-0.0625

0.25

4

0.82

In the study by Fallah, 54 eyes of 54 patients who developed recurrent pterygium after
having pterygium excision surgery were randomly divided into treatment and control groups and
followed for 3-6 months. Subjects were recruited from the Tehran University Eye Research
Center. The mean ages of the treatment group and control group were 49.96 and 51.61
respectively; the age ranges of the subjects were not provided. It was noted whether the patients
started the treatment 30 days prior to or 30 days following pterygium surgery. Means of
progression of fibrovascular tissue were measured in the first week, first month, and three
months of follow up after treatment was given to each of the groups.
The data in the study was continuous, and was unable to be converted into dichotomous
data. The duration of progression of fibrovascular tissue to invasion of the cornea was calculated,
and results were analyzed using the software SPSS version 13. All patients in both groups failed,
meaning that fibrovascular tissue spread onto the cornea. However, Table 4 shows there was a
statistical significance difference (p<0.01) in time in which this happened between the groups.
The duration for invasion of cornea was longer in the treatment group, and the mean progression
of fibrovascular tissue was less than in the control group. Table 5 shows there was also a
statistical significance in the time needed for invasion of the cornea with fibrovascular tissue in
treatment patients compared to control patients when the drugs were started less than 30 days
and more than 30 days following surgery.
Table 4: Progression after starting treatment4
Treatment group

Control group

P value

De la Cruz: Bevacizumab and Pterygium 10
One week

1.916± 0.375

2.740± 0.517

<0.01

One month

15.998± 1.22

27.230± 4.700

<0.01

Three months

37.671± 13.1

59.247± 9 .472

<0.01

Time for corneal invasion (days)

90.538±51.569

44.892±18.905

<0.001

Table 5: Duration for corneal invasion following initiation of treatment after surgery4
<30 days

>30 days

P value

Treatment group

119.6± 52.6

61.4± 30.5

0.002

Control group

54.0± 20.8

34.3± 8.4

0.004

DISCUSSION
This systematic review investigated three RCTs for the effectiveness of Bevacizumab
in inhibiting the growth of recurrent pterygium. Each article selected subjects who had recurrent
pterygium after having previous pterygium excision surgery. The blinding during the 3 RCTs
was without error, and none of the subjects withdrew from the experiments.
Bevacizumab is a monoclonal antibody considered to be an anti-angiogenesis agent
due to its ability to inhibit VEGF.5 It is currently approved by the FDA to be used as a first line
drug against metastatic colorectal cancer.5 Some of the most common systemic side effects
include epistaxis, thromboembolic events, hypertension, rhinitis, and proteinuria.5 Intravitreal
Bevacizumab has been used as an off label treatment of age related macular degeneration with
good results.11 Although no systemic side effects and no obvious safety outliers have been noted
with intravitreal use, more studies need to be done to determine the safety of topical
Bevacizumab.11
All three studies used different dosages of Bevacizumab, and in one of the studies
Bevacizumab was given along with a topical corticosteroid. There were several limitations
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expressed by each study. The study by Lekhanont noted that the dose of Bevacizumab given
might have been insufficient to have the desired effect.8 The treatment was given 2.5 months
after the excision surgery, and it was noted that the treatment might have been more effective if
given sooner after surgery, before regrowth of fibrovascular tissue already occurred.8 Small
sample size and short follow up time were further limitations noted.8 The study by Fallah noted
that the quantity and limited amount of time Bevacizumab was administered to subjects was the
main possibility for the treatment’s failure.4 Finally, the study by Ozgurhan noted that the small
sample size and short follow up time were the main limitations in the study.10
CONCLUSIONS
Two of the studies showed that Bevacizumab is not an effective treatment in inhibiting
the growth of recurrent pterygium; however, they showed that it delayed the recurrence of the
disorder. The other study showed inhibition of growth in pterygium, however, the results were
not statistically significant. Therefore, the evidence analyzed in this systematic review is
inconclusive. Future study is warranted to evaluate topical Bevacizumab as a treatment to inhibit
the growth of recurrent pterygium before routine use can be recommended and approved by the
FDA.
Future studies evaluating the effectiveness of Bevacizumab should include larger study
groups within the United States. There should also be a more consistent amount of time between
the pterygium excision surgery and the start of treatment in the study groups. The results of the
studies analyzed in this systematic review demonstrated significant potential of Bevacizumab to
inhibit recurrent pterygium. Current ongoing studies are being done in England and in the U.S. to
determine the effectiveness of Bevacizumab in the treatment of choroidal neovascularization
which will help shed light on the safety of the drug when applied topically.11
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